How do triallists decide the two key features of a trial: which patients and what endpoints? And what is the future for SGLT2 inhibitors in heart failure? Darrel Francis speaks to PI, and lead author, Milton Packer, about the double-blind EMPEROR-Reduced trial which was published in New England Journal of Medicine on 29th August 2020.

+ posts

Leave a Reply